Fredun Pharmaceuticals

₹1,521As of Sun 8 Nov 2026, 12:00 UTC

NSE:FREDUNHealthcare

Country India

PE (Fwd) 54.98

TSR 10Y CAGR —

Div yield 0.02%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.87

PE TTM 74.55

TSR TTM —

Mkt cap ₹25.12B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹1,682

10.59%

(86.87%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

6.355

Revenue₹B

—

2.245

2.747

3.482

4.538

6.355

7.441

29.71%

40.03

Revenue growth%

—

22.37

26.75

30.35

40.03

17.09

28.55

—

25.71

Gross margin%

—

17.91

20.23

20.82

22.90

25.71

25.78

20.82

13.00

Operating margin%

—

5.23

9.16

9.85

10.71

13.00

13.13

9.85

5.13

Net margin%

—

2.82

3.93

4.49

4.35

5.13

5.17

4.35

74.55

P/E ratio (avg)x

—

63.24

—

29.43

EV/EBITx

—

24.90

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

20.41

EPS₹

—

5.09

8.04

11.22

14.17

20.41

24.06

41.53%

—

43.98

EPS growth%

—

58.16

39.47

26.34

43.98

17.88

41.72

—

Bookvalue per sh₹

—

FCF per share₹

—

0.23

Dividend per sh₹

—

0.23

0.24

—

0.02

Div yield (avg)%

—

0.02

—

1.14

Payout ratio%

—

4.59

2.90

2.08

1.65

1.14

1.00

2.08

15.98

Shares (diluted)M

—

12.46

13.43

13.93

15.98

◌15.98

6.43%

(14.78)

Buyback yield%

—

(7.85)

(3.66)

—

(14.78)

◌—

(5.76)

—

D/E ratiox

—

24.32

Enterprise value₹B

—

24.32

—

LT debt₹M

—

Peers (US$259.5M)

Cap (US$)

Hikal Limited

286.1M

—

Sakar Healthcare…

231.0M

50.45x

Windlas Biotech Limited

219.2M

31.91x

Auxly Cannabis Group…

263.8M

11.20x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

2.204

2.674

Own earn%

—

Sh yield%

(14.76)

(5.76)

Owners

Insiders/Inst%

38.93

3.83

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

4/4

Dividend streakyrs

Op margin range%

5–13

$1 testx

—

Incr. ROIC%

—

Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, animal healthcare products, cosmeceuticals, mobility and rehabilitation products, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹6.355B

29.71%

1.00×

Cost of revenue

₹4.721B

26.52%

0.90×

Operating expenses

₹807.5M

29.79%

1.00×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m